306 related articles for article (PubMed ID: 25325988)
1. New approaches to selectively target cancer-associated matrix metalloproteinase activity.
Tauro M; McGuire J; Lynch CC
Cancer Metastasis Rev; 2014 Dec; 33(4):1043-57. PubMed ID: 25325988
[TBL] [Abstract][Full Text] [Related]
2. Seesaw of matrix metalloproteinases (MMPs).
Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
[TBL] [Abstract][Full Text] [Related]
3. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
Zucker S; Cao J; Chen WT
Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases and cancer - roles in threat and therapy.
Yadav L; Puri N; Rastogi V; Satpute P; Ahmad R; Kaur G
Asian Pac J Cancer Prev; 2014; 15(3):1085-91. PubMed ID: 24606423
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
Yang JS; Lin CW; Su SC; Yang SF
Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
[TBL] [Abstract][Full Text] [Related]
6. MMP inhibitors and cancer treatment trials, limitations and hopes for the future.
Tlatli R; El Ayeb M
Arch Inst Pasteur Tunis; 2013; 90(1-4):3-21. PubMed ID: 26012207
[TBL] [Abstract][Full Text] [Related]
7. Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.
Alcantara MB; Dass CR
J Pharm Pharmacol; 2014 Jul; 66(7):895-902. PubMed ID: 24697787
[TBL] [Abstract][Full Text] [Related]
8. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
Li W; Saji S; Sato F; Noda M; Toi M
Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic Roles of Metalloproteinases in Hematological Malignancies: an Update.
Chaudhary AK; Chaudhary S; Ghosh K; Nadkarni A
Asian Pac J Cancer Prev; 2016; 17(7):3043-51. PubMed ID: 27509927
[TBL] [Abstract][Full Text] [Related]
10. The other side of MMPs: protective roles in tumor progression.
Martin MD; Matrisian LM
Cancer Metastasis Rev; 2007 Dec; 26(3-4):717-24. PubMed ID: 17717634
[TBL] [Abstract][Full Text] [Related]
11. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.
Folgueras AR; Pendás AM; Sánchez LM; López-Otín C
Int J Dev Biol; 2004; 48(5-6):411-24. PubMed ID: 15349816
[TBL] [Abstract][Full Text] [Related]
13. Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes.
Winer A; Adams S; Mignatti P
Mol Cancer Ther; 2018 Jun; 17(6):1147-1155. PubMed ID: 29735645
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.
Radisky ES; Raeeszadeh-Sarmazdeh M; Radisky DC
J Cell Biochem; 2017 Nov; 118(11):3531-3548. PubMed ID: 28585723
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting.
Abdel-Hamid NM; Abass SA
Mol Biol Rep; 2021 Sep; 48(9):6525-6538. PubMed ID: 34379286
[TBL] [Abstract][Full Text] [Related]
16. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
Gialeli C; Theocharis AD; Karamanos NK
FEBS J; 2011 Jan; 278(1):16-27. PubMed ID: 21087457
[TBL] [Abstract][Full Text] [Related]
17. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
Piperigkou Z; Manou D; Karamanou K; Theocharis AD
Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
[TBL] [Abstract][Full Text] [Related]
18. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
19. Matrix Metalloproteinases (MMPs) in Targeted Drug Delivery: Synthesis of a Potent and Highly Selective Inhibitor against Matrix Metalloproteinase- 7.
Wang LL; Zhang B; Zheng MH; Xie YZ; Wang CJ; Jin JY
Curr Top Med Chem; 2020; 20(27):2459-2471. PubMed ID: 32703131
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy.
Artacho-Cordón F; Ríos-Arrabal S; Lara PC; Artacho-Cordón A; Calvente I; Núñez MI
Surg Oncol; 2012 Sep; 21(3):e143-51. PubMed ID: 22749313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
